A mouse study from Shasqi. The biopolymer was injected into one of two tumours and the doxorubicin prodrug given into the blood; both tumours responded and the mice lived longer.
A preclinical study of SQ3370 in mice bearing two tumours, of which only one was injected with the biopolymer before systemic doses of the attenuated doxorubicin prodrug. SQ3370 was well tolerated at 5.9 times the maximum dose of conventional doxorubicin, increased survival by 63 per cent and produced an anti-tumour response against both the injected and the non-injected lesion. The sustained response correlated with immune activation measured at both lesions, and the authors suggest the approach could help patients with micro-metastatic disease.
This is the animal evidence behind the hope that treating one injectable tumour could help disease elsewhere. In the human trial that followed, shrinkage of non-injected lesions was seen, but the overall response rate was no higher than with standard doxorubicin.
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Click-activated prodrugs (bioorthogonal drug activation in the body).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/